-
-
Login
A newly published correspondence in The Lancet Diabetes & Endocrinology has now reopened a debate that many healthcare systems believed had largely been settled: does wider CGM adoption always represent good value?
Teplizumab becomes the first NHS-approved treatment shown to delay the onset of type 1 diabetes. Given as a 14-day course of infusions before symptoms develop, the drug could postpone diagnosis by around two to three years and may signal the beginning of a new era in type 1 diabetes treatment.
